Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | JAK2 | O60674 | 1/20 | 0.60 |
| ▸ | MITF | O75030 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | EGFR | P00533 | 3/20 | 0.57 |
| ▸ | ABL1 | P00519 | 1/20 | 0.56 |
| ▸ | ABL2 | P42684 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7139086 | 1.00 | FBP1 (0.68) | FBP1ALDH1A1KMT2ALMNACYP1A2 | |
| SCHEMBL7139084 | 1.00 | FBP1 (0.68) | FBP1ALDH1A1KMT2ALMNACYP1A2 | |
| SCHEMBL30094390 | 0.85 | FBP1 (0.55) | FBP1ALDH1A1KMT2ALMNACYP1A2 | |
| SCHEMBL3605335 | 0.81 | FBP1 (0.57) | FBP1ALDH1A1KMT2ALMNACYP1A2 | |
| SCHEMBL3605327 | 0.81 | FBP1 (0.57) | FBP1ALDH1A1KMT2ALMNACYP1A2 | |
| SCHEMBL3605332 | 0.81 | FBP1 (0.57) | FBP1ALDH1A1KMT2ALMNACYP1A2 | |
| SCHEMBL1032131 | 0.81 | FBP1 (1.00) | FBP1ALDH1A1KMT2ALMNACYP1A2 | |
| SCHEMBL1127238 | 0.81 | FBP1 (1.00) | FBP1ALDH1A1KMT2ALMNACYP1A2 | |
| SCHEMBL1749791 | 0.81 | FBP1 (1.00) | FBP1ALDH1A1KMT2ALMNACYP1A2 | |
| SCHEMBL3922572 | 0.80 | FBP1 (0.65) | FBP1ALDH1A1KMT2ALMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210061762-A1 | P300/CBP HAT INHIBITORS | CONSTELLATION PHARMACEUTICALS, INC. | 2021-03-04 | — | — | US | disclosed |
| EP-0928790-B1 | Thiazole derivatives | HOFFMANN LA ROCHE (CH) | 2003-03-05 | — | — | EP | disclosed |
| US-6344562-B1 | ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. | 2002-02-05 | — | — | US | disclosed |
| US-20020010316-A1 | Thiazole derivatives | ALIG LEO (CH) | 2002-01-24 | — | — | US | disclosed |
| US-6320054-B1 | INHIBIT BINDING OF ADHESIVE PROTEINS TO THE SURFACE OF DIFFERENT TYPES F CELL AND ACCORDINGLY INFLUENCE CELL-CELL AND CELL-MATRIX INTERACTIONS. | HOFFMAN-LA ROCHE INC. | 2001-11-20 | — | — | US | disclosed |
| US-6100282-A | Thiazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2000-08-08 | — | — | US | disclosed |
| EP-0928790-A1 | Thiazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-07-14 | — | — | EP | disclosed |
| US-4753962-A | HYPOGLYCEMIC, ANTIOBESITY AGENT | BEECHAM GROUP P.L.C. (GB) | 1988-06-28 | — | — | US | disclosed |
| US-4654371-A | ANTI-OBESITY, HYPOGLYCEMIA AGENTS | BEECHAM GROUP P.L.C. (GB) | 1987-03-31 | — | — | US | disclosed |
| US-4493843-A | Indole and indoline carboxylic acid compounds and method of use | MAY & BAKER LIMITED (GB) | 1985-01-15 | — | — | US | disclosed |
| US-4478849-A | HYPERGLYCEMIC AGENTS | BEECHAM GROUP LIMITED (GB) | 1984-10-23 | — | — | US | disclosed |
| EP-0042298-B1 | INDOLE AND INDOLINE DERIVATIVES | MAY & BAKER LIMITED (GB) | 1984-09-12 | — | — | EP | disclosed |
| EP-0006735-B1 | SECONDARY AMINES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE | BEECHAM GROUP PLC (GB) | 1983-06-15 | — | — | EP | disclosed |
| EP-0042298-A1 | Indole and indoline derivatives | MAY & BAKER LIMITED (GB) | 1981-12-23 | — | — | EP | disclosed |
| EP-0006735-A1 | Secondary amines, their preparation, pharmaceutical compositions containing them and their use | BEECHAM GROUP PLC (GB) | 1980-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010316-A1 | Thiazole derivatives | VCAM1, SOST, TGFB1 | FBP1 2082/4885ALDH1A1 1400/4885KMT2A 4510/4885 |
| US-20210061762-A1 | P300/CBP HAT INHIBITORS | EP300, HDAC1, KAT2A | FBP1 616/4885ALDH1A1 1211/4885KMT2A 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.